Market Overview

Momentum Stock Soliton Continues Rally Following News Of Cellulite Trial Initiation

Share:
Momentum Stock Soliton Continues Rally Following News Of Cellulite Trial Initiation

Medical device company Soliton Inc. (NASDAQ: SOLY) shares are trading higher again after the company announced its decision to move forward with a pivotal trial after positive data from its proof-of-concept trial to reduce cellulite.

What To Know

The FDA approved method for long-term reduction of cellulite is an invasive treatment called Cellfina that produced an average improvement on the same scale of about 2 points.

Soliton's cellulite study is to take place at multiple clinical sites across the country with between 45 and 60 patients to be treated in the study. It will begin within the next three months.

Why It's Important

"The market for non-invasive cellulite treatments is about $1 billion in the U.S., so it is clear that many women who are affected by the condition are interested in finding ways to reduce or eliminate it," said co-founder Walter Klemp in a press release. "The procedure requires no recovery time and avoids the risks that go with even minimally invasive surgery."

Soliton's stock traded higher by 33 percent to $18.93 per share at time of publication Wednesday afternoon. The stock opened Tuesday under $6 per share.

Related Links:

Soliton Rallies On FDA Approval For Tattoo Removal Device

Soliton Responds To Blog Calling It A 'PR Machine'

Photo courtesy of Soliton.

Posted-In: News Health Care Movers Trading Ideas General Best of Benzinga

 

Related Articles (SOLY)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

42 Stocks Moving In Wednesday's Mid-Day Session

Charlotte's Web Says Friday TSX Listing 'A Milestone For The Overall Industry'